Autor segons l'article: Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez-Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M
Departament: Medicina i Cirurgia
Autor/s de la URV: Gumà Padró, José
Paraules clau: Treatment Non-hodgkin-lymphoma Guideline Diffuse large b-cell lymphoma Diagnosis treatment single-arm r-chop plus rituximab phase-3 open-label multicenter guideline epoch-r elderly-patients diagnosis chemotherapy
Resum: Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.© 2023. The Author(s).
Àrees temàtiques: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: jose.guma@urv.cat
Identificador de l'autor: 0000-0001-7541-9832
Data d'alta del registre: 2024-08-03
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://link.springer.com/article/10.1007/s12094-023-03206-5
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinical & Translational Oncology. 25 (9): 2749-2758
Referència de l'ítem segons les normes APA: Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez-Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio (2023). SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clinical & Translational Oncology, 25(9), 2749-2758. DOI: 10.1007/s12094-023-03206-5
DOI de l'article: 10.1007/s12094-023-03206-5
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2023
Tipus de publicació: Journal Publications